Although most studies in large cohorts report a panel of CSF markers, including α-synuclein (α-syn), amyloid beta peptide 1–42 (Aβ1–42) and phosphorylated tau (181P) (p-tau), total tau (t-tau), were useful in distinguishing PD from controls [1, 3], the data between studies are not consistent due to variation in group sizes, pre-analytical confounding factors and assay characteristics [4–7]. The gene discussed is MAPT; the disease is Parkinson disease.